Earnings Releases·Nov 5, 2026, 4:07 PM ET

Natera — Third Quarter 2026 Earnings Summary

Total revenue grew 34.1% year-over-year to $794.0 million, while the net loss narrowed to $59.9 million ($0.42 per share) from $87.5 million in the prior-year period.
Management raised 2026 annual revenue guidance midpoint by $140 million to $3.005–$3.035 billion and projects positive cash flow for the full year.
Test volume increased 22.3% to 1.09 million units, driven by a 60.9% surge in oncology tests and higher average selling prices.
Operating expenses rose 19.5% to $576.1 million due to headcount growth and clinical trial costs, though gross margin remained stable at 64.7%.
The company maintains a strong liquidity position with $1.097 billion in cash and restricted cash, alongside $80.3 million in total debt.